Calls
1
Dr. Dean Lee
President, Merck Research Laboratories
Win Rate
100.0%
return
+1.6%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Aug 19
$151.04
+1.6%
Dr. Dean Lee argues the Phase 3 data show adding Moderna's personalized cancer treatment to Keytruda reduced recurrence or death in high-risk melanoma, extending the Keytruda franchise. He notes Keytruda is already approved across 20 cancer types, its first success was melanoma, providing a roadmap for lung, bladder, kidney, stomach and pancreas trials, and regulators are already familiar with the technology.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Dr. Dean Lee has 1 trade ideas tracked on Buzzberg across 1 tickers since August 2026. Most covered: MRK.
